Adenoidzystische Karzinome (AZK) der Kopf-Hals-Region sind hÄufiger in den kleinen SpeicheldrÜsen, insbesondere am Gaumen (25%) und den NasennebenhÖhlen (11%) lokalisiert. Die geringe Symptomatik, das langsame Tumorwachstum und die Infiltration entlang des Perineuriums oder der KnochenkanÄlchen erklÄren das hÄufig bereits bei der Erstdiagnose fortgeschrittene Tumorstadium. Die Art dieses Tumorwachstums fÜhrt zu einer hohen Rate von Lokalrezidiven (80%), sowie hÄmatogenen (30%), seltener lymphogenen Metastasen (5%). Diese Wachstumskinetik bestimmt den oft langen klinischen Verlauf und die schlechte Prognose der AZK. Seit 1979 wurden an der HNO-Klinik Innsbruck insgesamt 17 Patienten mit AZK unterschiedlicher Lokalisation behandelt. Bei einer medianen Nachbeobachtungszeit von 6 Jahren werden unsere Ergebnisse nach operativem sowie strahlentherapeutischem Vorgehen dargelegt. Drei Patienten werden vorgestellt, um auf den typischen klinischen Verlauf des AZK hinzuweisen.

Keywords:
Adenoid cystic carcinoma, Salivary gland carcinoma, Minor salivary glands, Palate, Paranasal sinuses
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.